We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing ALX148 as a foundational checkpoint immunotherapy

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, ALX148, will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.

Latest News updated at 00:34:29 UTC

Jan 11, 2021

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021

Jan 05, 2021

ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference

Dec 17, 2020

ALX Oncology Added to the NASDAQ Biotechnology Index

Twitter

ALX Oncology provides corporate update and highlights key milestones in 2021: https://bit.ly/3nwD1v5 #JPM2021

ALX Oncology has announced a presentation at #JPM21 on Tuesday, January 12 at 10:50 am ET: https://bit.ly/2JLYuT3 #JPM2021

ALX Oncology announces updated data from ASPEN-01, the ongoing Phase 1b study of ALX148, showing robust, durable activity in patients with non-Hodgkin lymphoma, at #ASH2020. View the poster at: https://bit.ly/3lQqNfZ #ASH20

Load More...

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, ALX148, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.

LEARN MORE